Molecular analysis of synchronous and metachronous tumors of the lung: Impact on management and prognosis

Jiaoti Huang, Carmen Behrens, Ignacio Wistuba, Adi F. Gazdar, Jaishree Jagirdar

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Patients with pulmonary neoplasms have an increased risk for developing a second tumor of the lung, either at the same time or different times. It is important to determine if the second tumor represents an independent primary tumor (ie, a synchronous or a metachronous tumor, depending on whether it is present at the same time or a later time) or recurrence/metastasis, because it will significantly change the management and prognosis. Because the two tumors from the same patient are often morphologically similar, histologic examination alone may not be sufficient to distinguish between the two possibilities. We have attempted to approach this problem by microdissecting malignant cells and comparing patterns of loss of heterozygosity of multiple genes and chromosomal loci between paired tumors. We found that primary tumors of the lung and their metastasis share nearly identical patterns of loss of heterozygosity. In contrast, most synchronous and metachronous tumors as defined by the current arbitrary criteria appeared to be genetically different; therefore, they likely represented independent primary tumors. Rare synchronous tumors had similar genetic profiles, raising the possibility of recurrence/metastasis. Our data suggest that molecular analysis can help fingerprint tumors and has the potential to significantly impact management and prognosis of patients.

Original languageEnglish (US)
Pages (from-to)321-329
Number of pages9
JournalAnnals of Diagnostic Pathology
Volume5
Issue number6
DOIs
StatePublished - 2001

Fingerprint

Lung
Neoplasms
Loss of Heterozygosity
Neoplasm Metastasis
Recurrence
Dermatoglyphics
Lung Neoplasms
Genes

Keywords

  • Loss of heterozygosity
  • Lung cancer
  • Metachronous
  • Microdissection
  • Synchronous

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Molecular analysis of synchronous and metachronous tumors of the lung : Impact on management and prognosis. / Huang, Jiaoti; Behrens, Carmen; Wistuba, Ignacio; Gazdar, Adi F.; Jagirdar, Jaishree.

In: Annals of Diagnostic Pathology, Vol. 5, No. 6, 2001, p. 321-329.

Research output: Contribution to journalArticle

Huang, Jiaoti ; Behrens, Carmen ; Wistuba, Ignacio ; Gazdar, Adi F. ; Jagirdar, Jaishree. / Molecular analysis of synchronous and metachronous tumors of the lung : Impact on management and prognosis. In: Annals of Diagnostic Pathology. 2001 ; Vol. 5, No. 6. pp. 321-329.
@article{344a4be0130240ea8399da4ac513e68b,
title = "Molecular analysis of synchronous and metachronous tumors of the lung: Impact on management and prognosis",
abstract = "Patients with pulmonary neoplasms have an increased risk for developing a second tumor of the lung, either at the same time or different times. It is important to determine if the second tumor represents an independent primary tumor (ie, a synchronous or a metachronous tumor, depending on whether it is present at the same time or a later time) or recurrence/metastasis, because it will significantly change the management and prognosis. Because the two tumors from the same patient are often morphologically similar, histologic examination alone may not be sufficient to distinguish between the two possibilities. We have attempted to approach this problem by microdissecting malignant cells and comparing patterns of loss of heterozygosity of multiple genes and chromosomal loci between paired tumors. We found that primary tumors of the lung and their metastasis share nearly identical patterns of loss of heterozygosity. In contrast, most synchronous and metachronous tumors as defined by the current arbitrary criteria appeared to be genetically different; therefore, they likely represented independent primary tumors. Rare synchronous tumors had similar genetic profiles, raising the possibility of recurrence/metastasis. Our data suggest that molecular analysis can help fingerprint tumors and has the potential to significantly impact management and prognosis of patients.",
keywords = "Loss of heterozygosity, Lung cancer, Metachronous, Microdissection, Synchronous",
author = "Jiaoti Huang and Carmen Behrens and Ignacio Wistuba and Gazdar, {Adi F.} and Jaishree Jagirdar",
year = "2001",
doi = "10.1053/adpa.2001.29338",
language = "English (US)",
volume = "5",
pages = "321--329",
journal = "Annals of Diagnostic Pathology",
issn = "1092-9134",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Molecular analysis of synchronous and metachronous tumors of the lung

T2 - Impact on management and prognosis

AU - Huang, Jiaoti

AU - Behrens, Carmen

AU - Wistuba, Ignacio

AU - Gazdar, Adi F.

AU - Jagirdar, Jaishree

PY - 2001

Y1 - 2001

N2 - Patients with pulmonary neoplasms have an increased risk for developing a second tumor of the lung, either at the same time or different times. It is important to determine if the second tumor represents an independent primary tumor (ie, a synchronous or a metachronous tumor, depending on whether it is present at the same time or a later time) or recurrence/metastasis, because it will significantly change the management and prognosis. Because the two tumors from the same patient are often morphologically similar, histologic examination alone may not be sufficient to distinguish between the two possibilities. We have attempted to approach this problem by microdissecting malignant cells and comparing patterns of loss of heterozygosity of multiple genes and chromosomal loci between paired tumors. We found that primary tumors of the lung and their metastasis share nearly identical patterns of loss of heterozygosity. In contrast, most synchronous and metachronous tumors as defined by the current arbitrary criteria appeared to be genetically different; therefore, they likely represented independent primary tumors. Rare synchronous tumors had similar genetic profiles, raising the possibility of recurrence/metastasis. Our data suggest that molecular analysis can help fingerprint tumors and has the potential to significantly impact management and prognosis of patients.

AB - Patients with pulmonary neoplasms have an increased risk for developing a second tumor of the lung, either at the same time or different times. It is important to determine if the second tumor represents an independent primary tumor (ie, a synchronous or a metachronous tumor, depending on whether it is present at the same time or a later time) or recurrence/metastasis, because it will significantly change the management and prognosis. Because the two tumors from the same patient are often morphologically similar, histologic examination alone may not be sufficient to distinguish between the two possibilities. We have attempted to approach this problem by microdissecting malignant cells and comparing patterns of loss of heterozygosity of multiple genes and chromosomal loci between paired tumors. We found that primary tumors of the lung and their metastasis share nearly identical patterns of loss of heterozygosity. In contrast, most synchronous and metachronous tumors as defined by the current arbitrary criteria appeared to be genetically different; therefore, they likely represented independent primary tumors. Rare synchronous tumors had similar genetic profiles, raising the possibility of recurrence/metastasis. Our data suggest that molecular analysis can help fingerprint tumors and has the potential to significantly impact management and prognosis of patients.

KW - Loss of heterozygosity

KW - Lung cancer

KW - Metachronous

KW - Microdissection

KW - Synchronous

UR - http://www.scopus.com/inward/record.url?scp=0035665338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035665338&partnerID=8YFLogxK

U2 - 10.1053/adpa.2001.29338

DO - 10.1053/adpa.2001.29338

M3 - Article

C2 - 11745069

AN - SCOPUS:0035665338

VL - 5

SP - 321

EP - 329

JO - Annals of Diagnostic Pathology

JF - Annals of Diagnostic Pathology

SN - 1092-9134

IS - 6

ER -